Alan Lunt1,2, Emily McGhee1, Karl Sylvester1, Gerrard Rafferty1,2, Moira Dick3, David Rees3, Susan Height3, Swee Lay Thein4, Anne Greenough1,2. 1. Division of Asthma, Allergy, and Lung Biology MRC Center for Allergic Mechanisms in Asthma, King's College London, London, United Kingdom. 2. National Institute for Health Research (NIHR), Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust and King's College London, London, United Kingdom. 3. Department of Paediatric Haematology, King's College Hospital NHS Foundation Trust, London, United Kingdom. 4. Division of Gene and Cell Based Therapy, King's College London School of Medicine at Guy's, King's College and St Thomas' Hospitals, London, United Kingdom.
Abstract
OBJECTIVES: To prospectively assess longitudinal lung function in children with sickle cell disease (SCD). WORKING HYPOTHESIS: Lung function in SCD children deteriorates with increasing age and the decline is more marked in younger children who have recently suffered ACS episodes. STUDY DESIGN: Two prospective longitudinal studies. PATIENT-SUBJECT SELECTION: Two cohorts of SCD children and age and ethnic matched controls were recruited. Cohort One (47 SCD and 26 controls) had a median age of 8.8 years and follow up of 2 years and Cohort Two (45 SCD and 26 controls) a median age of 10.2 years and follow up of 10 years. METHODOLOGY: Forced expiratory volume in one second (FEV1 ), vital capacity (VC), forced expiratory flow between 25% and 75% of VC (FEF 25-75 ), total lung capacity (TLC) and residual volume (RV) were measured on two occasions. RESULTS: In both groups of SCD children, lung function declined significantly, but in neither control group. ACS episodes were more frequent during the follow up period in Cohort One than Cohort Two (P < 0.0001). The rate of decline was greater in Cohort One than Cohort Two for FEV1 (P = 0.008), VC (P = 0.001), FEF25-75 (P = 0.030), TLC (P = 0.004), and RV (P = 0.043). In Cohort Two restrictive abnormalities were more common at follow up (P = 0.006). CONCLUSIONS: Lung function deteriorated with increasing age in SCD children and the rate of decline was greater in younger children in whom ACS episodes were more common. Pediatr Pulmonol. 2016;51:717-723.
OBJECTIVES: To prospectively assess longitudinal lung function in children with sickle cell disease (SCD). WORKING HYPOTHESIS: Lung function in SCD children deteriorates with increasing age and the decline is more marked in younger children who have recently suffered ACS episodes. STUDY DESIGN: Two prospective longitudinal studies. PATIENT-SUBJECT SELECTION: Two cohorts of SCD children and age and ethnic matched controls were recruited. Cohort One (47 SCD and 26 controls) had a median age of 8.8 years and follow up of 2 years and Cohort Two (45 SCD and 26 controls) a median age of 10.2 years and follow up of 10 years. METHODOLOGY: Forced expiratory volume in one second (FEV1 ), vital capacity (VC), forced expiratory flow between 25% and 75% of VC (FEF 25-75 ), total lung capacity (TLC) and residual volume (RV) were measured on two occasions. RESULTS: In both groups of SCD children, lung function declined significantly, but in neither control group. ACS episodes were more frequent during the follow up period in Cohort One than Cohort Two (P < 0.0001). The rate of decline was greater in Cohort One than Cohort Two for FEV1 (P = 0.008), VC (P = 0.001), FEF25-75 (P = 0.030), TLC (P = 0.004), and RV (P = 0.043). In Cohort Two restrictive abnormalities were more common at follow up (P = 0.006). CONCLUSIONS: Lung function deteriorated with increasing age in SCD children and the rate of decline was greater in younger children in whom ACS episodes were more common. Pediatr Pulmonol. 2016;51:717-723.
Authors: Sara C Sadreameli; Rachel O Alade; Peter J Mogayzel; Sharon McGrath-Morrow; John J Strouse Journal: Pediatr Allergy Immunol Pulmonol Date: 2017-12-01 Impact factor: 1.349
Authors: Shaina M Willen; Robyn Cohen; Mark Rodeghier; Fenella Kirkham; Susan S Redline; Carol Rosen; Jane Kirkby; Michael R DeBaun Journal: Am J Hematol Date: 2018-01-25 Impact factor: 10.047
Authors: Robert I Liem; Sophie Lanzkron; Thomas D Coates; Laura DeCastro; Ankit A Desai; Kenneth I Ataga; Robyn T Cohen; Johnson Haynes; Ifeyinwa Osunkwo; Jeffrey D Lebensburger; James P Lash; Theodore Wun; Madeleine Verhovsek; Elodie Ontala; Rae Blaylark; Fares Alahdab; Abdulrahman Katabi; Reem A Mustafa Journal: Blood Adv Date: 2019-12-10
Authors: Deborah Friedman; Allen J Dozor; Jordan Milner; Marise D'Souza; Julie-An Talano; Theodore B Moore; Shalini Shenoy; Qiuhu Shi; Mark C Walters; Elliott Vichinsky; Susan K Parsons; Suzanne Braniecki; Chitti R Moorthy; Janet Ayello; Allyson Flower; Erin Morris; Harshini Mahanti; Sandra Fabricatore; Liana Klejmont; Carmella van de Ven; Lee Ann Baxter-Lowe; Mitchell S Cairo Journal: Bone Marrow Transplant Date: 2021-05-06 Impact factor: 5.483
Authors: Ana Karine Vieira; Cristina Gonçalves Alvim; Maria Cristina Marquez Carneiro; Cássio da Cunha Ibiapina Journal: J Bras Pneumol Date: 2016 Nov-Dec Impact factor: 2.624
Authors: A Parker Ruhl; S Christy Sadreameli; Julian L Allen; Debra P Bennett; Andrew D Campbell; Thomas D Coates; Dapa A Diallo; Joshua J Field; Elizabeth K Fiorino; Mark T Gladwin; Jeffrey A Glassberg; Victor R Gordeuk; Leroy M Graham; Anne Greenough; Jo Howard; Gregory J Kato; Jennifer Knight-Madden; Benjamin T Kopp; Anastassios C Koumbourlis; Sophie M Lanzkron; Robert I Liem; Roberto F Machado; Alem Mehari; Claudia R Morris; Folasade O Ogunlesi; Carol L Rosen; Kim Smith-Whitley; Danna Tauber; Nancy Terry; Swee Lay Thein; Elliott Vichinsky; Nargues A Weir; Robyn T Cohen; Elizabeth S Klings Journal: Ann Am Thorac Soc Date: 2019-09